The use of novel hemostatic sealant (Tisseel®) in laparoscopic myomectomy: a case–control study

Angioli, Roberto; Plotti, Francesco; Ricciardi, Roberto; Terranova, Corrado; Zullo, Marzio Angelo; Damiani, Paul; Montera, Roberto; Guzzo, Federica; Saglio, Giuseppe; Muzii, Ludovico

doi:10.1007/s00464-012-2154-2

Cited by 16 publications

(13 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of HA during laparoscopic gynecologic procedures was evaluated in 1 study involving myomectomy, 5 studies in adnexal procedures (including cystectomy, sterilization, and salpingotomy for ectopic pregnancy), 1 study during sterilization, and 1 study for repair of uterine perforation. 14–21 No studies evaluating HA use at time of laparoscopic hysterectomy for benign indication were found.…”

Section: Resultsmentioning

confidence: 99%

“…The same study observed a significant reduction in operative time when the fibrin sealant was used ( p < .05). 14 Another type of fibrin sealant, Tachosil (Baxter Healthcare Corporation, Deerfield, IL, USA), was evaluated in a prospective cohort study of 129 with respect to potential benefits on ovarian reserve during laparoscopic ovarian cystectomy. Floseal (Baxter Healthcare Corporation, Deerfield, IL, USA), a thrombin-gelatin matrix, was another agent of interest in this article.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic Review of Topical Hemostatic Agent Use in Minimally Invasive Gynecologic Surgery

Ito

Martin

Henderson

et al. 2018

JSLS

View full text Add to dashboard Cite

Background and Objectives:To perform a systematic review of articles evaluating hemostatic effectiveness and peri-operative outcomes when topical hemostatic agents (HA) are used in minimally invasive gynecologic surgeries (MIGS) for benign conditions.Methods:Studies published through March 31, 2017 were retrieved through PubMed, EMBASE, Cochrane, and ClinicalTrials.gov to identify all eligible studies. No studies were excluded based on publish date. All comparative studies or case series with >10 participants reporting use of at least one topical HA in MIGS for benign conditions were included as long as full-text articles were available and written in English. Studies were excluded if surgery was done for malignancy or completed via an open approach. Articles that included multiple surgical subspecialties were excluded if data related to MIGS was unable to be isolated. Evaluation for eligibility and data extraction was performed by three independent reviewers. Quality of evidence was also assessed by each reviewer.Results:From 132 articles, a total of 8 studies were included in this systematic review. We found that use of fibrin sealant decreased time to hemostasis, postoperative hemoglobin drop, and estimated blood loss (EBL) compared with bipolar energy and reduced the overall operative time in laparoscopic myomectomy. When fibrin sealant use at time of myomectomy was compared to bipolar energy there was no significant difference in the rate of postoperative complications. Furthermore, there was less of a decrease in anti-Mullerian hormone (AMH) level when a thrombin-gelatin matrix was used compared to bipolar energy on ovarian tissue.Conclusion:Application of topical HA in MIGS can reduce operative time, blood loss, and ameliorate damage to ovarian function. However, more data needs to be gathered for use of HA during different types of gynecologic procedures (adnexal surgery, myomectomy, and hysterectomy) to provide better quality evidence to guide their use.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Systematic Review of Topical Hemostatic Agent Use in Minimally Invasive Gynecologic Surgery

Ito

Martin

Henderson

et al. 2018

JSLS

View full text Add to dashboard Cite

show abstract

“…In another historically controlled ( n = 15) prospective series of patients ( n = 15) over 2 years, fibrin sealant was used as an adjunct to hemostasis on uterine closure sutures during laparoscopic myomectomy [282]. Significant benefit to using fibrin sealant was noted for operative time (47.7 versus 62.1 min, P < 0.05), time to achieve complete hemostasis (195.5 versus 361.8 sec, P < 0.0001), estimated blood loss (111.3 versus 230 mL, P < 0.05), and mean decrease in hemoglobin (1.36 versus 2.04 g/dL, P < 0.05).…”

Section: Less Frequently Published Clinical Applications Of Fibrinmentioning

confidence: 99%

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

2014

View full text Add to dashboard Cite

Background. Fibrin sealant became the first modern era material approved as a hemostat in the United States in 1998. It is the only agent presently approved as a hemostat, sealant, and adhesive by the Food and Drug Administration (FDA). The product is now supplied as patches in addition to the original liquid formulations. Both laboratory and clinical uses of fibrin sealant continue to grow. The new literature on this material also continues to proliferate rapidly (approximately 200 papers/year). Methods. An overview of current fibrin sealant products and their approved uses and a comprehensive PubMed based review of the recent literature (February 2012, through March 2013) on the laboratory and clinical use of fibrin sealant are provided. Product information is organized into sections based on a classification system for commercially available materials. Publications are presented in sections based on both laboratory research and clinical topics are listed in order of decreasing frequency. Results. Fibrin sealant remains useful hemostat, sealant, and adhesive. New formulations and applications continue to be developed. Conclusions. This agent remains clinically important with the recent introduction of new commercially available products. Fibrin sealant has multiple new uses that should result in further improvements in patient care.

show abstract

“…The postoperative hemoglobin (Hb) change is an objective parameter of intraoperative blood loss after LM [4, 5, 8, 18, 21, 23] and correlates better with the actual blood loss than a subjective estimation [24]. Studies on predictors of intraoperative blood loss in LM are rare.…”

Section: Introductionmentioning

confidence: 99%

Predictors of postoperative hemoglobin drop after laparoscopic myomectomy.

Watrowski

Jäger

Förster

2017

Videosurgery and Other Miniinvasive Techniques

View full text Add to dashboard Cite

IntroductionLaparoscopic myomectomy (LM) can be associated with significant bleeding.AimTo identify factors influencing the postoperative hemoglobin (Hb) drop after LM.Material and methodsThis is a retrospective, single-center study. We evaluated data of 150 consecutive patients undergoing LM due to intramural myomas between 2010 and 2015.ResultsThe median age of the patients was 37 (23–53) years. The mean diameter of the largest myoma was 5.7 ±2.3 (1.5–12) cm. The mean surgical time was 83 ±38 (35–299) min. The median number of sutures was 3 (1–11). The mean postoperative Hb drop was 1.6 ±1.2 (0–6) g/dl, and the mean estimated blood loss was 261 ±159 (50–1700) ml. In the univariate analysis, the postoperative Hb drop correlated with the duration of surgery (p < 0.001), diameter of the largest myoma (p < 0.001), cumulative myoma weight (p < 0.001), and number of sutures (p < 0.001), but not with patients’ age or number of intramural myomas. In the multivariable analysis, the surgical time (β = 0.395, p < 0.001), diameter of the largest myoma (β = 0.292, p = 0.03) and preoperative Hb concentration (β = 0.299, p < 0.001) predicted the postoperative Hb change.ConclusionsSurgical time and dominant myoma diameter are independent predictors of the postoperative Hb drop after LM.

show abstract

The use of novel hemostatic sealant (Tisseel®) in laparoscopic myomectomy: a case–control study

Cited by 16 publications

References 49 publications

Systematic Review of Topical Hemostatic Agent Use in Minimally Invasive Gynecologic Surgery

Systematic Review of Topical Hemostatic Agent Use in Minimally Invasive Gynecologic Surgery

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

Predictors of postoperative hemoglobin drop after laparoscopic myomectomy.

Contact Info

Product

Resources

About